<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03876574</url>
  </required_header>
  <id_info>
    <org_study_id>NPC11330</org_study_id>
    <nct_id>NCT03876574</nct_id>
  </id_info>
  <brief_title>Hepatic Artery Infusion Pump for NPC Liver Metastases</brief_title>
  <official_title>Hepatic Artery Infusion Gemcitabine and Floxuridine in Patients With Nasopharyngeal Carcinoma Liver Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xiangya Hospital of Central South University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A retrospective clinical trial to study the safety and effectiveness of hepatic arterial&#xD;
      infusion (HAI) in treating patients who have nasopharyngeal carcinoma metastatic to the&#xD;
      liver. Hepatic-direction drug administration improves the control power for intra-hapatic&#xD;
      lesions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the safety and toxicity of hepatic arterial infusion with gemcitabine,&#xD;
      floxuridine and dexamethasone in combination with standard treatment (radiotherapy and&#xD;
      systemic chemotherapy) in patients with nasopharyngeal carcinoma metastases to liver.&#xD;
&#xD;
      II. Determine the objective response of intrahepatic lesions of patients treated with this&#xD;
      regimen.&#xD;
&#xD;
      III. Determine the median survival time or overall survival time in patients treated with&#xD;
      this regimen.&#xD;
&#xD;
      OUTLINE: This is a single-center retrospective study.&#xD;
&#xD;
      Patients receive DSA-guided implantation of HAI catheter system. HAI is initiated the next&#xD;
      day. Gemcitabine intra-arterially for 30 minutes on day 1,8, floxuridine, dexamethasone&#xD;
      intra-arterially continuously on days 1-14. Treatment repeats every 3 weeks in the absence of&#xD;
      serious technical catheter-related problems, progression of intrahepatic lesions or&#xD;
      unacceptable toxicity. Standard treatment of NPC, including radiotherapy and chemotherapy&#xD;
      (induction chemotherapy, concurrent chemotherapy and adjuvant chemotherapy) was performed as&#xD;
      desired.&#xD;
&#xD;
      Patients are followed every 2 HAI cycles or when necessary.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2011</start_date>
  <completion_date type="Actual">December 31, 2017</completion_date>
  <primary_completion_date type="Actual">December 31, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease control rate (DCR) of intrahepatic lesions</measure>
    <time_frame>2 years</time_frame>
    <description>Assess the Disease control rate (DCR) of intrahepatic lesions by enhanced spiral-CT scan according to RECIST criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival time</measure>
    <time_frame>7 years</time_frame>
    <description>From the date of HAI catheter implantation to the date of death from any cause or to completion of trial, whichever comes first, up to 84 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects and adverse events</measure>
    <time_frame>2 years</time_frame>
    <description>To determine the safety and tolerability of HAI for NPC liver metastases by establishing the rates of toxicity</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <condition>Neoplasm Metastasis</condition>
  <condition>Liver</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo DSA-guided implantation of hepatic artery infusion pump. All patients receive the intervention &quot;Hepatic artery infusion of gemcitabine and floxuridine&quot; the next day after pump implantation. The HAI therapy is initiated on day 1, 8: Gemcitabine 1g/m2 for 30 minutes, followed by a blended solution which comprised floxuridine (FUDR) at 0.15 mg/kg/day, dexa-methasone (DXM) at 1 mg/m2/day, low molecular heparin 3200U and saline, lasted for 7 days continuously.Standard treatments of NPC, including radiotherapy and chemotherapy (induction chemotherapy, concurrent chemotherapy and adjuvant chemotherapy) are performed as desired.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>DSA-guided implantation of hepatic artery infusion pump</intervention_name>
    <description>Implant the infusion catheter and injection port (Celsite, B. Braun, Chasseneuil, France) under DSA-guiding. The proximal end of the infusion catheter was connected to the injection port and the device was implanted in a subcutaneous pocket in the right inner thigh; the distal end of the infusion catheter guarantee uni-direction infusion to liver.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Given intra-arterially for 30 minutes</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Floxuridine</intervention_name>
    <description>Given intra-arterially continuously for 14 days</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>5-FUDR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <description>Given intra-arterially continuously with 5-FUDR</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>DXM</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed nasopharyngeal carcinoma with histologically confirmed or&#xD;
             image diagnosed metastatic to the liver&#xD;
&#xD;
          -  Standard treatment of NPC, including radiotherapy and chemotherapy (induction&#xD;
             chemotherapy, concurrent chemotherapy and adjuvant chemotherapy) is performed as&#xD;
             desired&#xD;
&#xD;
          -  Performance status - ECOG 0-2&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,200/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST no greater than 2.5 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 2.5 times ULN&#xD;
&#xD;
          -  No pre-existing chronic hepatic disease (chronic active hepatitis or cirrhosis)&#xD;
&#xD;
          -  Creatinine no greater than ULN&#xD;
&#xD;
          -  Creatinine clearance greater than 60 mL/min&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Adequate oral nutrition (at least 1,500 calories/day)&#xD;
&#xD;
          -  Able to withstand major operative procedure&#xD;
&#xD;
          -  No dehydration&#xD;
&#xD;
          -  No severe anorexia&#xD;
&#xD;
          -  No frequent nausea or vomiting&#xD;
&#xD;
          -  No prior or concurrent malignancy within the past 5 years except basal cell or&#xD;
             squamous cell skin cancer or carcinoma in situ of any organ&#xD;
&#xD;
          -  No prior or concurrent malignancy associated with more than 10% probability of death&#xD;
             from malignant disease within 5 years of diagnosis&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
          -  No concurrent colony-stimulating factors during the first course of study therapy&#xD;
&#xD;
          -  No more than 1 prior adjuvant systemic fluorouracil (5-FU) regimen with or without&#xD;
             levamisole, leucovorin calcium, or irinotecan&#xD;
&#xD;
          -  No prior hepatic artery infusion therapy with 5-FU or floxuridine&#xD;
&#xD;
          -  No prior systemic chemotherapy for metastatic disease&#xD;
&#xD;
          -  No prior or concurrent sorivudine or brivudine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>March 3, 2019</study_first_submitted>
  <study_first_submitted_qc>March 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2019</study_first_posted>
  <last_update_submitted>March 12, 2019</last_update_submitted>
  <last_update_submitted_qc>March 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatic artery infusion pump</keyword>
  <keyword>Gemcitabine</keyword>
  <keyword>Floxuridine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Floxuridine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

